|1.||Bachar, Sitesh C: 3 articles (07/2010 - 07/2008)|
|2.||Bachar, Sitesh Chandra: 2 articles (09/2012 - 10/2005)|
|3.||Nahar, Lutfun: 2 articles (09/2012 - 07/2010)|
|4.||Kundu, Joydeb Kumar: 2 articles (09/2012 - 10/2005)|
|5.||Nieto, Jorge E: 2 articles (01/2012 - 08/2011)|
|6.||Aleman, Monica: 2 articles (01/2012 - 08/2011)|
|7.||Foreman, J H: 2 articles (11/2011 - 02/2008)|
|8.||Datta, Bidyut K: 2 articles (07/2010 - 07/2008)|
|9.||Maciążek-Jurczyk, Małgorzata: 1 article (10/2014)|
|10.||van Loon, J P A M: 1 article (07/2014)|
07/01/2014 - "Although phenylbutazone (PBZ) is commonly used in equine orthopaedic practice, little is known about its in vivo effects on joint inflammation and cartilage turnover. "
01/01/2008 - "Compounds 3f and 3i were found to be most active compound of this series, which shows 46.42% and 50% inflammation inhibitory activity, whereas standard drug phenylbutazone exhibit 53.57% antiinflammatory activity at a dose of 50 mg/kg po."
08/01/2002 - "Compounds 7b and 6'b were found to be potent member of this series, which showed 50.66 and 47.56%, respectively, inflammation inhibitory activity at a dose of 50 mg kg(-1) p.o., while standard drug, phenylbutazone, exhibited 45.52% anti-inflammatory activity at the same dose. "
12/01/1996 - "The effect of inflammation on the disposition of phenylbutazone (PBZ) was investigated in Thoroughbred horses. "
12/01/1996 - "The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses."
07/15/2005 - "Phenylbutazone administered PO did not effectively alleviate signs of thoracolumbar pain in horses in this study."
03/01/2011 - "In the XX century, nonsteroidal anti-inflammatory drugs were synthesized, such as phenylbutazone, which was initially considered primarily a pain medication. "
02/01/2008 - "The objective was to test the hypothesis that phenylbutazone (PBZ) alleviates lameness in an adjustable heart bar shoe model of equine foot pain. "
01/01/1989 - "With phenylbutazone the post-operative swelling was not significantly reduced compared to placebo, but there was less pain and limping. "
03/01/1987 - "All ponies were given phenylbutazone orally for relief of ocular pain. "
|3.||Body Weight (Weight, Body)
01/01/1997 - "Because serum concentration of phenylbutazone after single i.v. bolus administration (4.4 mg/kg of body weight) decreases more rapidly in donkeys, compared with horses, phenylbutazone may require more frequent administration in donkeys to achieve therapeutic efficacy."
12/01/1998 - "Milk clearance of phenylbutazone was 0.009 mL/h/kg body weight, or about 0.34% of total body clearance. "
01/01/2011 - "All these effects were compared with reference drug phenylbutazone (100 mg/kg body weight)."
07/01/2010 - "Maximum inhibition by the extract was observed at 250 mg/kg body weight after three hours of ingestion, which was comparable to that of the standard drug phenylbutazone at a dose of 100 mg/kg body weight. "
02/28/2008 - "From the nine fractions (A-I) obtained, of an initial chromatographic separation, fractions A and E (doses equivalents to 1.50 g dry plant/kg body weight) showed the strongest anti-inflammatory activity comparable to that of the reference drug phenylbutazone (80 mg/kg). "
05/01/1982 - "Fr.L showed significant activity in preventing ulcer formation and gastric juice secretion in pylorus-ligated rats, and was also effective in reducing index of the phenylbutazone-induced ulcer."
01/01/1956 - "[Hepatorenal lesions in the course of experimental ulcers caused by phenylbutazone in dogs; observations on the protective effects of gastrointestinal extracts]."
03/01/1982 - "[Studies on gastric mucosal prostaglandin in phenylbutazone ulcer rats (author's transl)]."
11/01/1966 - "[Variations in the histaminopexic power of serum in ulcers induced by butazolidin (experimental study)]."
04/01/1982 - "Phenylbutazone caused exacerbation by the administration for 5 days at the middle stage of the ulcer healing process. "
01/01/2013 - "The test compounds 1 and 2 displayed signiﬁcant inhibitory activity at a dose of 1 mg/ear on edema formation at all determination times, with similar intensity as phenylbutazone."
11/01/1999 - "Percentage inhibition of edema by butanolic extract (33.05, P < 0.001) is comparable to that of phenylbutazone, 100 mg/kg inhibition (38.83%). "
11/01/1986 - "The compounds were generally only 1/2 to 3 times as potent as phenylbutazone in the rat paw edema antiinflammatory assay. "
01/01/1982 - "Percent inhibition of the paw edema volume by phenylbutazone (50 mg/kg p. "
01/01/1975 - "These compounds were three to five times more active than phenylbutazone as assessed from ED30 values determined on rat paw edema 5 hr after single oral doses."
|2.||Aspirin (Acetylsalicylic Acid)